Formulary restrictions may impact enrollment in pragmatic trials and limit generalizability of findings to vulnerable populations

Kent DM Rothwell PM Ioannidis JP , et al. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials 2010; 11: 85.

Lesko CR Henderson NC Varadhan R . Considerations when assessing heterogeneity of treatment effect in patient-centered outcomes research. J Clin Epidemiol 2018; 100: 22–31.

Varadhan R Segal JB Boyd CM , et al. A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research. J Clin Epidemiol 2013; 66(8): 818–825.

Center for Medicare Medicaid Services. Assuring medicaid beneficiaries access to hepatitis C HCV drugs, https://www.medicaid.gov/medicaid-chip-program-information/by-topics/prescription-drugs/downloads/rx-releases/state-releases/state-rel-172.pdf (2015, accessed 22 April 2020).

Gordon SC Trudeau S Li J , et al. Race, age, and geography impact hepatitis C genotype distribution in the United States. J Clin Gastroenterol 2019; 53(1): 40–50.

White IR Horton NJ Carpenter J , et al. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ 2011; 342: d40.

Balakrishnan AS Palmer NR Fergus KB , et al. Minority recruitment trends in phase III prostate cancer clinical trials (2003 to 2014): progress and critical areas for improvement. J Urol 2019; 201(2): 259259–259267.

Chino F Zafar SY . Financial toxicity and equitable access to clinical trials. Am Soc Clin Oncol Educ Book 2019; 39: 11–18.

CATT Research Group, Martin DF Maguire MG , et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897–1908.

Wilder JM Jeffers LJ Ravendhran N , et al. Safety and efficacy of ledipasvir–sofosbuvir in black patients with hepatitis C virus infection: a retrospective analysis of phase 3 data. Hepatology 2016; 63(2): 437–444.